NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma"
The purpose of this study is to evaluate the safety of NINLARO in participants with relapsed/refractory multiple myeloma in daily clinical practice.
Relapsed/Refractory Multiple Myeloma
DRUG: Ixazomib
Number of Participants Reporting One or More Adverse Events (AEs), An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment., Up to 24 Week (From start of administration to the end of 6 cycles)|Number of Participants Who Had One or More Adverse Drug Reactions (ADRs), An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. Adverse drug reaction (ADR) refers to AE related to administered drug., Up to 24 Week (From start of administration to the end of 6 cycles)
The drug being tested in this study is called Ixazomib (NINLARO). Ixazomib is being tested to treat people who have relapsed/refractory multiple myeloma. This study will look at the safety of NINLARO in participants with relapsed/refractory multiple myeloma in daily clinical practice.

The study will enroll approximately 480 patients.

â€¢ Ixazomib 4 mg

This multi-center trial will be conducted in Japan.